**Journal of Hepatology**

**CTAT methods**

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

* Only include the parts relevant to your study
* Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
* Do not add subheadings
* Add as many rows as needed to include all information
* Only include one item per row

**If the CTAT form is not relevant to your study, please outline the reasons why:**

|  |
| --- |
|  |

* 1. **Antibodies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Cat no.** | **Clone no.** |
|  |  |  |  |  |

* 1. **Cell lines**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Cat no.** | **Passage no.** | **Authentication test method** |
|  |  |  |  |  |  |

* 1. **Organisms**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Citation** | **Supplier** | **Strain** | **Sex** | **Age** | **Overall n number** |
| Human liver-chimeric PXB-Mouse® | <https://www.phoenixbio.com/products/pxb-mouse> | PhoenixBio, New York, NY, USA | PXB-Mouse® | Male | 12-18 weeks | 32 |

* 1. **Sequence based reagents**

|  |  |  |
| --- | --- | --- |
| **Name** | **Sequence** | **Supplier** |
|  |  |  |

* 1. **Biological samples**

|  |  |  |
| --- | --- | --- |
| **Description** | **Source** | **Identifier** |
|  |  |  |

* 1. **Deposited data**

|  |  |  |
| --- | --- | --- |
| **Name of repository** | **Identifier** | **Link** |
|  |  |  |

* 1. **Software**

|  |  |  |
| --- | --- | --- |
| **Software name** | **Manufacturer** | **Version** |
|  |  |  |

* 1. **Other (e.g. drugs, proteins, vectors etc.)**

|  |  |  |
| --- | --- | --- |
| ALN-HBV (subcutaneous injection) | Alnylam Pharmaceuticals | siRNA that targets a site complementary to a 19-nucleotide sequence matching to position 1577 to 1596 of the HBV genome that is encoded in all major HBV messenger RNA transcripts |
| VIR-2218 (subcutaneous injection) | Alnylam Pharmaceuticals/Vir Biotechnology, Inc. | siRNA identical to ALN-HBV except for the single substitution of a glycol nucleic acid modification |

* 1. **Please provide the details of the corresponding methods author for the manuscript:**

|  |
| --- |
| Daniel J. Cloutier, Vir Biotechnology Inc., San Francisco, CAdcloutier@vir.bio |

**2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.**

|  |
| --- |
| The clinical protocols of the randomized controlled trials are included in this submission. |